SERA
What one share of Sera Prognostics holds
Services – Medical Laboratories
We are a women’s health company utilizing our proprietary proteomics and bioinformatics platform, and significant data resources to improve maternal and neonatal health by discovering, developing, and commercializing blood-based biomarker tests, and predictive analytic products and services.
Sera Prognostics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $0.00 |
|---|---|
| Profit | −$0.66 |
| Capex (buildings and equipment) | $0.01 |
| Free cash flow | −$0.56 |
| Cash and investments | $1.59 |
| Book value | $1.18 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2020 | $0.02 | −$12.76 | $0.10 | −$10.94 | — | −$80.71 |
| 2021 | $0.01 | −$2.33 | $0.09 | −$2.20 | — | $9.24 |
| 2022 | $0.01 | −$1.43 | $0.03 | −$1.14 | — | $3.20 |
| 2023 | $0.01 | −$1.16 | $0.00 | −$0.88 | — | $2.25 |
| 2024 | $0.00 | −$0.99 | $0.00 | −$0.43 | — | $1.44 |
| 2025 | $0.00 | −$0.67 | $0.02 | −$0.55 | — | $1.58 |